Business Context and Reporting Period
Company: Sarepta Therapeutics, Inc. (SRPT)
Filing Type: Form 10-K (Annual Report)
Reporting Period: Fiscal year ended December 31, 2025
Business Overview: Sarepta is a commercial-stage biopharmaceutical company focused on RNA-targeted therapeutics, siRNA, and gene therapies for rare diseases, primarily Duchenne muscular dystrophy (DMD). The company commercializes four FDA-approved products: EXONDYS 51, VYONDYS 53, AMONDYS 45 (PMO products), and ELEVIDYS (gene therapy).
Key Financial Metrics (Year Ended Dec 31, 2025)
| Metric | 2025 Value | 2024 Value |
|---|---|---|
| Total Revenues | $2,198.2 million | $1,902.0 million |
| Net Product Revenues | $1,864.3 million | $1,788.0 million |
| Collaboration & Other Revenues | $333.9 million | $114.0 million |
| Operating Loss | $(699.8) million | $218.1 million (Income) |
| Net Loss | $(713.4) million | $235.2 million (Income) |
| Cash, Cash Equivalents & Investments | $953.8 million | $1,503.5 million |
| Long-Term Debt (Carrying Value) | $829.0 million | $1,137.1 million |
| Working Capital | $1,442.6 million | $2,341.8 million |
Material Changes vs. Prior Period
- Revenue Growth: Total revenue increased 16% year-over-year, driven by a 9% increase in ELEVIDYS sales ($898.7M) and a 193% surge in collaboration revenue ($333.9M) due to Roche milestone payments and option expirations.
- Profitability Reversal: The company swung from a net income of $235.2M in 2024 to a net loss of $713.4M in 2025. This was primarily driven by a $883.8M increase in R&D expenses (including $583.6M for Arrowhead IPR&D and $300M in Arrowhead milestones) and a $165.3M inventory write-down for excess/obsolete stock.
- Cost of Sales: Increased 163% to $839.6M, largely due to inventory valuation reserves, depletion of previously expensed inventory, and higher manufacturing costs.
- Debt Restructuring: The company exchanged $991.4M of 2027 Notes for 2030 Notes, cash, and stock, reducing total debt principal but increasing the interest rate on the new 2030 Notes to 4.875%.
- Restructuring: A strategic restructuring plan announced in July 2025 resulted in a $42.0M charge and a 36% workforce reduction.
Guidance, Outlook, Risks, and Unusual Items
Management Commentary & Outlook
Management believes current cash, cash equivalents, and investments ($953.8M), along with the $600M revolving credit facility, are sufficient to fund operations for at least the next 12 months. The company is prioritizing its siRNA platform and reducing costs to meet 2027 financial obligations.
Material Risks and Contingencies
- ELEVIDYS Safety & Suspension: Following reports of acute liver failure (ALF) in non-ambulatory patients, the FDA required a boxed warning and the removal of non-ambulatory patients from the label. Shipments to non-ambulatory patients remain suspended. Ambulatory shipments resumed in July 2025 after a temporary hold.
- ESSENCE Trial Results: Top-line results announced in November 2025 for the confirmatory trial of VYONDYS 53 and AMONDYS 45 did not meet statistical significance on the primary endpoint. This creates uncertainty regarding the continued accelerated approval of these products.
- LGMD Clinical Hold: The FDA placed a clinical hold on the company's LGMD gene therapy programs (including SRP-9003) in July 2025 following a patient death in a related trial. The company is awaiting data from a sirolimus study before re-engaging with the FDA.
- Inventory Write-Downs: A $165.3M charge was recorded for excess and obsolete inventory, primarily related to ELEVIDYS and PMO products, reflecting demand uncertainty following regulatory actions.
- Arrowhead Collaboration: A major new collaboration with Arrowhead Pharmaceuticals incurred significant upfront costs ($583.6M IPR&D expense) and milestone payments ($300M) in 2025.
Key Facts for Investor Verification
- Regulatory Status of PMO Products: Verify the FDA's response to the failed ESSENCE trial results and the potential for label changes or withdrawal of accelerated approval for VYONDYS 53 and AMONDYS 45.
- ELEVIDYS Non-Ambulatory Pathway: Monitor the results of the Cohort 8 study evaluating sirolimus as an immunosuppressant, which is a prerequisite for resuming commercial dosing in non-ambulatory patients.
- Liquidity vs. Debt Service: Assess the company's ability to service its $893.4M of 2030 Notes (maturing 2030) and $158.6M of 2027 Notes (maturing 2027) given the shift to a net loss position and high R&D burn rate.
- Inventory Valuation: Review future inventory write-down risks, as the company has already recorded significant reserves for excess stock due to the ELEVIDYS suspension and label changes.
- Arrowhead Milestone Obligations: Confirm the schedule for the remaining $250M in annual fees and potential future milestone payments under the Arrowhead Collaboration Agreement.